Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 10/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | TPH1 | P17752 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11933125 | 0.95 | SCN9A (0.35) | FPR2KDM1APDE4AACACBALOX5AP | |
| SCHEMBL11933115 | 0.93 | KDM1A (0.40) | FPR2KDM1APDE4AALOX5APFEN1 | |
| SCHEMBL11933184 | 0.89 | PDE4A (0.33) | FPR2KDM1APDE4AHTR2CHTR2B | |
| SCHEMBL15381674 | 0.87 | KDM1A (0.39) | FPR2KDM1APDE4A | |
| SCHEMBL15381671 | 0.87 | KDM1A (0.44) | FPR2KDM1APDE4ATPH1 | |
| SCHEMBL11933308 | 0.86 | ALOX5AP (0.37) | FPR2ALOX5APFEN1 | |
| SCHEMBL11933208 | 0.86 | NAAA (0.34) | FPR2KDM1APDE4A | |
| SCHEMBL10008735 | 0.85 | KDM1A (0.38) | FPR2KDM1APDE4A | |
| SCHEMBL10008737 | 0.85 | KDM1A (0.38) | FPR2KDM1APDE4A | |
| SCHEMBL11933331 | 0.85 | FFAR1 (0.40) | ACACBALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580147-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-11-12 | — | — | US | disclosed |
| US-20120168677-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120168677-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CXCR1, OCIAD1, LEO1 | FPR2 804/4885KDM1A 1622/4885PDE4A 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.